The viral main protease is one of the most attractive targets among all key enzymes involved
in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine145 of SARS-CoV-2 MPRO …

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) identified in 2003
infected∼ 8000 people in 26 countries with 800 deaths, which was soon contained and …

The main protease (Mpro) of SARS-CoV-2 is a validated antiviral drug target. Several Mpro
inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity …

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …

Although vaccines are available for SARS-CoV-2, antiviral drugs such as nirmatrelvir are still
needed, particularly for individuals in whom vaccines are less effective, such as the …

Mpro, the main protease of the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), is essential for the viral life cycle. Accordingly, several groups have performed in …

As an essential enzyme of SARS-CoV-2, the COVID-19 pathogen, main protease (M Pro) is
a viable target to develop antivirals for the treatment of COVID-19. By varying chemical …

The global spread of SARS-CoV-2 has proceeded at an unprecedented rate. Remarkably,
characterization of the virus using modern tools in structural biology has also progressed at …

The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of
antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3C …